Royalty Pharma vs Opko Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Royalty Pharma Plc (RPRX)

Q3 202629 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

July 202629 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

Latest29 Jun – 13 Aug 2026

▲4

Royalty Pharma Raises Guidance Again, Adds AstraZeneca Royalty

Q2 beat and second guidance raise Royalty Pharma beat expectations and raised its 2026 outlook for the second quarter in a row, now guiding to $3.4–3.5 billion in portfolio receipts. Strong sales of Tremfya, Voranigo, Emdeltra and Evrysdi drove the beat, signaling its royalty base keeps growing.
This is the core new fundamental driver of the period and directly lifts future earnings expectations.
New AstraZeneca cliramitug royalty deal Royalty Pharma is paying up to $425 million for a 3–4% royalty on AstraZeneca's cliramitug, a Phase 3 heart drug for ATTR-CM. With peak sales seen at $3–5 billion, this adds a potential $110–190 million in annual royalty revenue later this decade.
This is a fresh capital deployment that expands the royalty portfolio and future cash flow.
Lupus drug litifilimab nears key data Royalty Pharma co-developed litifilimab with Biogen, and Phase 3 enrollment is complete with topline results due in the second half of 2026. Positive data would validate another late-stage pipeline asset and support future royalty growth.
It highlights a near-term clinical catalyst that could add a new royalty stream.
Stock hits 52-week high on earnings momentum RPRX touched $60.44 as investors reacted to 13% growth in first-quarter royalty receipts and the raised full-year outlook. The stock has gained 56% over the past year, reflecting growing confidence in the royalty model.
It shows the market is rewarding the company's consistent execution, reinforcing the positive trend.

Opko Health Inc (OPK)

Q3 202623 Jul – 14 Sep 2026

▲4

OPKO's Q2 Beat, Raised Guidance, and Royalty-Backed Cash Drive Gains

Q2 beat and raised 2026 revenue guidance OPKO reported Q2 revenue of $163.6 million, beating estimates, and raised full-year 2026 revenue guidance to $560–$585 million. The net loss narrowed to a penny a share from a huge loss a year earlier. This tells investors the business is stabilizing and growing, which pushes the stock up.
This is the core new financial event that directly lifted the stock and improved the outlook.
Pipeline progress and new CAR-T trial planned OPKO's ModeX platform is advancing multiple candidates, including BARDA-funded MDX2301, and the company plans first-in-human trials for its in vivo CAR-T asset MDX3001 by late 2026 or early 2027. New pipeline milestones give investors hope for future revenue beyond current products.
Pipeline advancement is a key reason investors are willing to look past current losses and bid the stock higher.
$125 million royalty-backed financing without dilution OPKO raised $125 million by issuing notes secured by its mazdutide royalty stream from Eli Lilly. This gives fresh cash without selling new shares, so existing investors are not diluted. The money can fund operations and pipeline trials, reducing financial risk and supporting the stock.
This new financing strengthens the balance sheet and is a direct positive for the stock.
Narrower losses and improved margins at BioReference OPKO's Q2 operating loss shrank to $7 million from $60 million a year earlier, and gross margin jumped to 48.9% from 31.5%. BioReference swung to a $4.8 million operating profit from a big loss, helped by cost cuts and an earnout gain. Better profitability supports the stock.
This explains the fundamental improvement that has driven the recent share price gain.

August 202623 Jul – 14 Sep 2026

▲4

OPKO's Q2 Beat, Raised Guidance, and Royalty-Backed Cash Drive Gains

Q2 beat and raised 2026 revenue guidance OPKO reported Q2 revenue of $163.6 million, beating estimates, and raised full-year 2026 revenue guidance to $560–$585 million. The net loss narrowed to a penny a share from a huge loss a year earlier. This tells investors the business is stabilizing and growing, which pushes the stock up.
This is the core new financial event that directly lifted the stock and improved the outlook.
Pipeline progress and new CAR-T trial planned OPKO's ModeX platform is advancing multiple candidates, including BARDA-funded MDX2301, and the company plans first-in-human trials for its in vivo CAR-T asset MDX3001 by late 2026 or early 2027. New pipeline milestones give investors hope for future revenue beyond current products.
Pipeline advancement is a key reason investors are willing to look past current losses and bid the stock higher.
$125 million royalty-backed financing without dilution OPKO raised $125 million by issuing notes secured by its mazdutide royalty stream from Eli Lilly. This gives fresh cash without selling new shares, so existing investors are not diluted. The money can fund operations and pipeline trials, reducing financial risk and supporting the stock.
This new financing strengthens the balance sheet and is a direct positive for the stock.
Narrower losses and improved margins at BioReference OPKO's Q2 operating loss shrank to $7 million from $60 million a year earlier, and gross margin jumped to 48.9% from 31.5%. BioReference swung to a $4.8 million operating profit from a big loss, helped by cost cuts and an earnout gain. Better profitability supports the stock.
This explains the fundamental improvement that has driven the recent share price gain.

Latest23 Jul – 14 Sep 2026

▲4

OPKO's Q2 Beat, Raised Guidance, and Royalty-Backed Cash Drive Gains

Q2 beat and raised 2026 revenue guidance OPKO reported Q2 revenue of $163.6 million, beating estimates, and raised full-year 2026 revenue guidance to $560–$585 million. The net loss narrowed to a penny a share from a huge loss a year earlier. This tells investors the business is stabilizing and growing, which pushes the stock up.
This is the core new financial event that directly lifted the stock and improved the outlook.
Pipeline progress and new CAR-T trial planned OPKO's ModeX platform is advancing multiple candidates, including BARDA-funded MDX2301, and the company plans first-in-human trials for its in vivo CAR-T asset MDX3001 by late 2026 or early 2027. New pipeline milestones give investors hope for future revenue beyond current products.
Pipeline advancement is a key reason investors are willing to look past current losses and bid the stock higher.
$125 million royalty-backed financing without dilution OPKO raised $125 million by issuing notes secured by its mazdutide royalty stream from Eli Lilly. This gives fresh cash without selling new shares, so existing investors are not diluted. The money can fund operations and pipeline trials, reducing financial risk and supporting the stock.
This new financing strengthens the balance sheet and is a direct positive for the stock.
Narrower losses and improved margins at BioReference OPKO's Q2 operating loss shrank to $7 million from $60 million a year earlier, and gross margin jumped to 48.9% from 31.5%. BioReference swung to a $4.8 million operating profit from a big loss, helped by cost cuts and an earnout gain. Better profitability supports the stock.
This explains the fundamental improvement that has driven the recent share price gain.